Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cygnus

This article was originally published in The Gray Sheet

Executive Summary

Proceeds of $18 mil. are raised through two offerings, including the "issuance of 8.5% fixed-rate convertible debentures for $14 mil., due June 29, 2004, with the right to sell an additional $6 mil. of debentures within the next year," and an additional $4 mil. from an equity line financing. Funds from the convertible debt, which is being managed by Palladin Group LP, will be used to redeem $12.5 mil. in existing floating rate convertible debt, which became convertible on July 1. "By establishing access to more capital through additional debentures and the equity line financing we should be able to fund certain activities in anticipation of the launch of the GlucoWatch monitor," Craig Carlson, senior VP-finance and chief financial officer comments in a July 1 release
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT011997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel